Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

AbbVie bets $1.4B on North Carolina pharma mega-campus

Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing

Plasmidsaurus expands RNA-Seq in Europe, partners with Genovis for ambient RNA shipping

The dual expansion simplifies transcriptomics workflows by combining faster regional turnaround with easier sample logistics

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Caplin Steriles gets USFDA approval for potassium phosphates injection

Caplin Steriles gets FDA approval for desmopressin

Desmopressin Acetate Injection is primarily used to treat central diabetes insipidus, haemophilia A, and von Willebrand disease

Glenmark Pharmaceuticals USA to launch sodium phosphates injection

The product addresses a market with approximately $66.8 million in annual sales as of December 2025.